Haplotypic structure across the IκBα gene (NFKBIA) and association with multiple myeloma

Cancer Letters

Volumn 246, Issue 1-2, 2007, Pages 92-99

  Spink, Charlotte F ^a   Gray, Lisa C ^a   Davies, Faith E ^b   Morgan, Gareth J ^b   Bidwell, Jeffrey L ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

I B; Induced heteroduplex generator; Multiple myeloma; NF B; Polymorphisms

Indexed keywords

GENE PRODUCT; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ARTICLE; CANCER GENETICS; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; DISEASE COURSE; DNA POLYMORPHISM; GENE; GENE LINKAGE DISEQUILIBRIUM; GENE STRUCTURE; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; HAPLOTYPE; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; NKFBIA GENE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ADULT; ALLELES; BASE SEQUENCE; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HUMANS; I-KAPPA B PROTEINS; LINKAGE DISEQUILIBRIUM; MOLECULAR SEQUENCE DATA; MULTIPLE MYELOMA; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE HOMOLOGY, NUCLEIC ACID;

EID: 33845657849     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.02.001     Document Type: Article

References (35)

1. Benjamin M., Reddy S., and Brawley O.W. Myeloma and race: a review of the literature. Cancer Metastasis Rev. 22 (2003) 87-93
2. Lynch H.T., Sanger W.G., Pirruccello S., Quinn-Laquer B., and Weisenburger D.D. Familial multiple myeloma: a family study and review of the literature. J. Natl Cancer Inst. 93 (2001) 1479-1483
3. Catz S.D., and Johnson J.L. Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 20 (2001) 7342-7351
4. Lai J.H., Horvath G., Subleski J., Bruder J., Ghosh P., and Tan T.H. RelA is a potent transcriptional activator of the CD28 response element within the interleukin 2 promoter. Mol. Cell. Biol. 15 (1995) 4260-4271
5. Shimizu H., Mitomo K., Watanabe T., Okamoto S., and Yamamoto K. Involvement of a NF-kappa B-like transcription factor in the activation of the interleukin-6 gene by inflammatory lymphokines. Mol. Cell. Biol. 10 (1990) 561-568
6. Collart M.A., Baeuerle P., and Vassalli P. Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four kappa B-like motifs and of constitutive and inducible forms of NF-kappa B. Mol. Cell. Biol. 10 (1990) 1498-1506
7. Guttridge D.C., Albanese C., Reuther J.Y., Pestell R.G., and Baldwin Jr. A.S. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell. Biol. 19 (1999) 5785-5799
8. Hinz M., Krappmann D., Eichten A., Heder A., Scheidereit C., and Strauss M. NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol. Cell. Biol. 19 (1999) 2690-2698
9. Mitsiades C.S., Mitsiades N., Poulaki V., Schlossman R., Akiyama M., Chauhan D., et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 21 (2002) 5673-5683
10. Iademarco M.F., McQuillan J.J., Rosen G.D., and Dean D.C. Characterization of the promoter for vascular cell adhesion molecule-1 (VCAM-1). J. Biol. Chem. 267 (1992) 16323-16329
11. Van de Stolpe A., Caldenhoven E., Stade B.G., Koenderman L., Raaijmakers J.A., Johnson J.P., and van der Saag P.T. 12-O-Tetradecanoylphorbol-13-acetate- and tumor necrosis factor alpha-mediated induction of intercellular adhesion molecule-1 is inhibited by dexamethasone. Functional analysis of the human intercellular adhesion molecular-1 promoter. J. Biol. Chem. 269 (1994) 6185-6192
12. Landowski T.H., Olashaw N.E., Agrawal D., and Dalton W.S. Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells. Oncogene 22 (2003) 2417-2421
13. Berenson J.R., Ma H.M., and Vescio R. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Semin. Oncol. 28 (2001) 626-633
14. Baeuerle P.A., and Baltimore D. NF-kappa B: ten years after. Cell 87 (1996) 13-20
15. Chiao P.J., Miyamoto S., and Verma I.M. Autoregulation of I kappa B alpha activity. Proc. Natl Acad. Sci. USA 91 (1994) 28-32
16. Richardson P.G., Hideshima T., and Anderson K.C. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 10 (2003) 361-369
17. Adams J., and Elliott P.J. New agents in cancer clinical trials. Oncogene 19 (2000) 6687-6692
18. Lightcap E.S., McCormack T.A., Pien C.S., Chau V., Adams J., and Elliott P.J. Proteasome inhibition measurements: clinical application. Clin. Chem. 46 (2000) 673-683
19. Hideshima T., Richardson P., Chauhan D., Palombella V.J., Elliott P.J., Adams J., and Anderson K.C. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61 (2001) 3071-3076
20. Moreira A.L., Corral L.G., Ye W., Johnson B., Stirling D., Muller G.W., et al. Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro. AIDS Res. Hum. Retroviruses 13 (1997) 857-863
21. Keifer J.A., Guttridge D.C., Ashburner B.P., and Baldwin Jr. A.S. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J. Biol. Chem. 276 (2001) 22382-22387
22. Jeremias I., Kupatt C., Baumann B., Herr I., Wirth T., and Debatin K.M. Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells. Blood 91 (1998) 4624-4631
23. Ito C.Y., Kazantsev A.G., and Baldwin Jr. A.S. Three NF-kappa B sites in the I kappa B-alpha promoter are required for induction of gene expression by TNF alpha. Nucleic Acids Res. 22 (1994) 3787-3792
24. Le Bail O., Schmidt-Ullrich R., and Israel A. Promoter analysis of the gene encoding the I kappa B-alpha/MAD3 inhibitor of NF-kappa B: positive regulation by members of the rel/NF-kappa B family. Eur. Mol. Biol. Org. J. 12 (1993) 5043-5049
25. Parker K.M., Ma M.H., Manyak S., Altamirano C.V., Tang Y.M., Frantzen M., et al. Identification of polymorphisms of the IkappaBalpha gene associated with an increased risk of multiple myeloma. Cancer Genet. Cytogenet. 137 (2002) 43-48
26. Stephens M., Smith N.J., and Donnelly P. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68 (2001) 978-989
27. Child J.A., Morgan G.J., Davies F.E., Owen R.G., Bell S.E., Hawkins K., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N. Engl. J. Med. 348 (2003) 1875-1883
28. Kane E.V., Roman E., Cartwright R., Parker J., and Morgan G. Tobacco and the risk of acute leukaemia in adults. Br. J. Cancer 81 (1999) 1228-1233
29. Morse H.R., Olomolaiye O.O., Wood N.A., Keen L.J., and Bidwell J.L. Induced heteroduplex genotyping of TNF-alpha, IL-1beta, IL-6 and IL-10 polymorphisms associated with transcriptional regulation. Cytokine 11 (1999) 789-795
30. Abecasis G.R., and Cookson W.O. GOLD-graphical overview of linkage disequilibrium. Bioinformatics 16 (2000) 182-183
31. Mozzato-Chamay N., Corbett E.L., Bailey R.L., Mabey D.C., Raynes J., and Conway D.J. Polymorphisms in the IkappaB-alpha promoter region and risk of diseases involving inflammation and fibrosis. Genes Immun. 2 (2001) 153-155
32. Abdallah A., Sato H., Grutters J.C., Veeraraghavan S., Lympany P.A., Ruven H.J., et al. Inhibitor kappa B-alpha (IkappaB-alpha) promoter polymorphisms in UK and dutch sarcoidosis. Genes Immun. 4 (2003) 450-454
33. Kim L.H., Shin H.D., Park B.L., Jung J.H., Kim J.Y., Kim Y.J., and Lee H.S. Identification of variants in NFKBIA and association analysis with hepatocellular carcinoma risk among chronic HBV patients. Hum. Mutat. 21 (2003) 652-653
34. Jungnickel B., Staratschek-Jox A., Brauninger A., Spieker T., Wolf J., Diehl V., et al. Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma. J. Exp. Med. 191 (2000) 395-402
35. Hideshima T., Chauhan D., Richardson P., Mitsiades C., Mitsiades N., Hayashi T., et al. NF-kappa B as a therapeutic target in multiple myeloma. J. Biol. Chem. 277 (2002) 16639-16647